38I.F
Intellia Therapeutics, Inc.
FrankfurtEUREQUITY
Healthcare
DELAYED
Last price
10.70
▲ 0.40 (3.88%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
10.70
Prev close
10.30
Day high
10.70
Day low
10.70
Volume
300
Market cap
$1.50B
P/E (TTM)
—
52W range
6.75 – 24.34
Day trading desk
Gap from prior close
+3.88%
Prior close 10.30
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
10.70 – 10.70
Position in range
—
—
ATR (14D)
0.58
5.40% of price
Prior day high
10.30
PDH
Prior day low
10.30
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 212
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+5.52%
+6.8%
1M
+11.34%
+8.1%
3M
-9.32%
-11.6%
6M
+0.09%
-11.7%
YTD
+43.47%
+31.6%
1Y
+20.44%
+0.4%
3Y
-68.87%
-143.7%
5Y
-91.95%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on 38I.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
5.40M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 22, 26 | DULAC EDWARD J III Chief Financial Officer |
SELL | 8.11K | $91.25K | Direct |
| Jul 2, 26 | DULAC EDWARD J III Chief Financial Officer |
SELL | 4.68K | $84.19K | Direct |
| Jul 1, 26 | DUBE MICHAEL P Officer |
SELL | 2.64K | $44.32K | Direct |
| Jun 9, 26 | COHEN FREDERICK E. M.D. PH.D. Director |
STOCK | 9.20K | $0 | Direct |
| Jun 9, 26 | VERWIEL FRANK Director |
STOCK | 9.20K | $0 | Direct |
| Jun 9, 26 | CHASE WILLIAM J Director |
STOCK | 9.20K | $0 | Direct |
| Jun 9, 26 | GOODMAN JESSE Director |
STOCK | 9.20K | $0 | Direct |
| Jun 9, 26 | KERESTY GEORGIA Director |
STOCK | 9.20K | $0 | Direct |
| Jun 9, 26 | BHANJI MUNA Director |
STOCK | 9.20K | $0 | Direct |
| Jun 9, 26 | GOFF BRIAN M Director |
STOCK | 9.20K | $0 | Direct |
| Mar 2, 26 | BASTA JAMES EDMUND General Counsel |
SELL | 1.21K | $16.69K | Direct |
| Mar 2, 26 | CLARK ELIANA Chief Technology Officer |
SELL | 607 | $8.36K | Direct |
| Feb 27, 26 | LEONARD JOHN M Chief Executive Officer |
STOCK | 156.40K | $0 | Direct |
| Feb 27, 26 | BASTA JAMES EDMUND General Counsel |
STOCK | 46.08K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BASTA JAMES EDMUND |
General Counsel | 156.79K | Sale |
CHASE WILLIAM J |
Director | 143.89K | Stock Award(Grant) |
CLARK ELIANA |
Chief Technology Officer | 93.86K | Sale |
COHEN FREDERICK E. M.D. PH.D. |
Director | 216.65K | Stock Award(Grant) |
DUBE MICHAEL P |
Officer | 66.89K | Sale |
DULAC EDWARD J III |
Chief Financial Officer | 148.18K | Sale |
LEBWOHL DAVID |
Officer | 131.19K | Stock Award(Grant) |
LEONARD JOHN M |
Chief Executive Officer | 1.23M | Stock Award(Grant) |
SCHULTES BIRGIT C PH.D. |
Officer | 137.73K | Stock Award(Grant) |
SEPP-LORENZINO LAURA |
Officer | 77.39K | Sale |
Fundamentals
Market cap$1.50B
Enterprise value$1.08B
Revenue (TTM)$59.51M
Gross profit$-222.82M
EBITDA$-414.40M
Net income$-399.98M
EPS (TTM)$-2.86
Free cash flow$-249.83M
Total cash$437.76M
Total debt$73.41M
Book value / share$4.45
Shares outstanding140.13M
Float134.42M
Short % of float—
Dividend yield—
Beta (5Y)1.79
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.12
PEG ratio—
Price / sales—
Price / book2.41
EV / revenue18.13
EV / EBITDA-2.60
Gross margin0.00%
Operating margin-1472.26%
Profit margin0.00%
Return on equity-55.44%
Return on assets-30.14%
Debt / equity10.09
Current ratio6.65
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $67.67M | $57.88M | $36.27M | $52.12M | +16.9% |
| Operating revenue | $67.67M | $57.88M | $36.27M | $52.12M | +16.9% |
| Research & development | $388.86M | $466.31M | $435.07M | $419.98M | -16.6% |
| Selling, general & admin | $119.80M | $125.83M | $116.50M | $90.31M | -4.8% |
| Total operating expense | $508.66M | $592.14M | $551.57M | $510.29M | -14.1% |
| Operating income | -$440.99M | -$534.26M | -$515.29M | -$458.16M | +17.5% |
| Net interest income | $29.20M | $47.81M | $49.83M | $8.54M | -38.9% |
| Pre-tax income | -$412.69M | -$519.02M | -$481.19M | -$474.19M | +20.5% |
| Net income | -$412.69M | -$519.02M | -$481.19M | -$474.19M | +20.5% |
| Net income to common | -$412.69M | -$519.02M | -$481.19M | -$474.19M | +20.5% |
| Basic EPS | -3.81 | -5.25 | -5.42 | -6.16 | +27.4% |
| Diluted EPS | -3.81 | -5.25 | -5.42 | -6.16 | +27.4% |
| EBIT | -$440.99M | -$534.26M | -$515.29M | -$458.16M | +17.5% |
| EBITDA | -$425.07M | -$523.98M | -$506.31M | -$450.59M | +18.9% |
| Basic shares | 108.38M | 98.85M | 88.77M | 76.97M | +9.6% |
| Diluted shares | 108.38M | 98.85M | 88.77M | 76.97M | +9.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $155.46M | $189.18M | $226.75M | $523.51M | -17.8% |
| Cash & short-term investments | $449.88M | $601.51M | $912.22M | $1.19B | -25.2% |
| Accounts receivable | $9.47M | $8.52M | $36.46M | $3.77M | +11.2% |
| Total current assets | $527.71M | $639.86M | $998.33M | $1.22B | -17.5% |
| Property, plant & equipment | $123.63M | $246.67M | $148.13M | $161.00M | -49.9% |
| Total assets | $842.13M | $1.19B | $1.30B | $1.52B | -29.3% |
| Total current liabilities | $103.88M | $110.85M | $115.21M | $126.55M | -6.3% |
| Total debt | $93.33M | $210.20M | $115.35M | $130.70M | -55.6% |
| Total liabilities | $170.73M | $319.06M | $250.81M | $284.53M | -46.5% |
| Retained earnings | -$2.59B | -$2.18B | -$1.66B | -$1.18B | -19.0% |
| Shareholder equity | $671.39M | $871.96M | $1.05B | $1.24B | -23.0% |
| Working capital | $423.83M | $529.01M | $883.12M | $1.09B | -19.9% |
| Net tangible assets | $671.39M | $871.96M | $1.05B | $1.24B | -23.0% |
| Shares issued | 116.32M | 102.03M | 93.00M | 87.10M | +14.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$412.69M | -$519.02M | -$481.19M | -$474.19M | +20.5% |
| Depreciation & amortisation | $15.92M | $10.29M | $8.98M | $7.57M | +54.8% |
| Stock-based compensation | $80.22M | $154.27M | $134.05M | $91.40M | -48.0% |
| Change in working capital | -$73.75M | $11.88M | -$52.45M | -$53.87M | -720.9% |
| Operating cash flow | -$394.74M | -$348.88M | -$394.09M | -$333.29M | -13.1% |
| Capital expenditure | -$1.13M | -$5.78M | -$13.98M | -$58.39M | +80.5% |
| Investing cash flow | $228.03M | $125.57M | -$31.35M | $160.31M | +81.6% |
| Financing cash flow | $131.49M | $185.75M | $130.32M | $582.96M | -29.2% |
| Free cash flow | -$395.87M | -$354.66M | -$408.07M | -$391.68M | -11.6% |
| End cash position | $167.57M | $202.79M | $240.35M | $535.46M | -17.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $7.66M | $15.05M | $23.02M | $13.78M | $14.24M | — | -49.1% |
| Operating revenue | $7.66M | $15.05M | $23.02M | $13.78M | $14.24M | — | -49.1% |
| Research & development | $82.59M | $80.74M | $88.65M | $94.75M | $97.03M | — | +2.3% |
| Selling, general & admin | $37.82M | $34.84M | $33.08M | $30.51M | $27.21M | — | +8.6% |
| Total operating expense | $120.42M | $115.58M | $121.73M | $125.26M | $124.24M | — | +4.2% |
| Operating income | -$112.76M | -$100.53M | -$98.71M | -$111.48M | -$110.00M | — | -12.2% |
| Net interest income | $5.80M | $5.21M | $6.48M | $6.71M | $7.40M | — | +11.4% |
| Pre-tax income | -$106.63M | -$96.23M | -$95.79M | -$101.32M | -$101.25M | — | -10.8% |
| Net income | -$106.63M | -$96.23M | -$95.79M | -$101.32M | -$101.25M | — | -10.8% |
| Net income to common | -$106.63M | -$96.23M | -$95.79M | -$101.32M | -$101.25M | — | -10.8% |
| Basic EPS | -0.80 | -0.81 | -0.83 | — | -0.98 | -1.10 | +1.2% |
| Diluted EPS | -0.80 | -0.81 | -0.83 | — | -0.98 | -1.10 | +1.2% |
| EBIT | -$112.76M | -$100.53M | -$98.71M | -$111.48M | -$110.00M | — | -12.2% |
| EBITDA | -$110.68M | -$98.33M | -$92.69M | -$106.54M | -$107.52M | — | -12.6% |
| Basic shares | 133.48M | 118.49M | 115.92M | — | 103.73M | 103.50M | +12.7% |
| Diluted shares | 133.48M | 118.49M | 115.92M | — | 103.73M | 103.50M | +12.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $106.13M | $134.70M | $155.46M | $193.39M | $156.17M | -21.2% |
| Cash & short-term investments | $437.76M | $375.99M | $449.88M | $511.04M | $459.65M | +16.4% |
| Accounts receivable | $7.32M | $9.13M | $9.47M | $11.05M | $11.35M | -19.8% |
| Total current assets | $527.83M | $466.45M | $527.71M | $581.94M | $495.94M | +13.2% |
| Property, plant & equipment | $101.01M | $113.06M | $123.63M | $138.30M | $188.68M | -10.7% |
| Total assets | $857.16M | $758.78M | $842.13M | $925.27M | $898.89M | +13.0% |
| Total current liabilities | $79.39M | $76.44M | $103.88M | $93.73M | $95.50M | +3.9% |
| Total debt | $73.41M | $80.49M | $93.33M | $97.97M | $102.59M | -8.8% |
| Total liabilities | $129.46M | $137.84M | $170.73M | $176.85M | $183.64M | -6.1% |
| Retained earnings | -$2.79B | -$2.69B | -$2.59B | -$2.49B | -$2.39B | -4.0% |
| Shareholder equity | $727.71M | $620.94M | $671.39M | $748.42M | $715.25M | +17.2% |
| Working capital | $448.44M | $390.00M | $423.83M | $488.21M | $400.45M | +15.0% |
| Net tangible assets | $727.71M | $620.94M | $671.39M | $748.42M | $715.25M | +17.2% |
| Shares issued | 139.72M | 120.45M | 116.32M | 115.79M | 105.33M | +16.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$106.63M | -$96.23M | -$95.79M | -$101.32M | -$101.25M | -10.8% |
| Depreciation & amortisation | $2.08M | $2.20M | $6.01M | $4.94M | $2.47M | -5.4% |
| Stock-based compensation | $18.07M | $13.48M | $16.74M | $19.60M | $22.04M | +34.1% |
| Change in working capital | $4.15M | -$37.16M | $494.00K | $4.41M | -$19.87M | +111.2% |
| Operating cash flow | -$83.11M | -$117.35M | -$69.28M | -$76.90M | -$99.62M | +29.2% |
| Capital expenditure | -$1.81M | -$79.00K | -$126.00K | -$29.00K | -$239.00K | -2,189.9% |
| Investing cash flow | -$141.57M | $66.31M | $27.53M | -$741.00K | $106.91M | -313.5% |
| Financing cash flow | $196.12M | $33.57M | $1.98M | $114.86M | $14.65M | +484.2% |
| Free cash flow | -$84.92M | -$117.42M | -$69.41M | -$76.93M | -$99.86M | +27.7% |
| End cash position | $121.53M | $150.10M | $167.57M | $207.34M | $170.13M | -19.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $9.77M | -29.1% |
| Next quarter | — | — | $17.09M | -25.8% |
| Current year | — | — | $51.88M | -23.3% |
| Next year | — | — | $125.47M | +141.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders3.86%
Held by institutions99.91%
Institutions holding435
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.29
+3.94% from price
SMA 20
9.85
+8.61% from price
SMA 50
11.52
-7.09% from price
SMA 100
11.59
-7.66% from price
SMA 200
10.63
+0.68% from price
EMA 12
10.25
+4.42% from price
EMA 26
10.39
+2.97% from price
EMA 50
10.84
-1.34% from price
RSI (14)
52.2
Neutral
MACD (12,26,9)
-0.14
Hist 0.19
ATR (14)
0.58
5.40% of price
Realised vol 30D
88.6%
Annualised
Bollinger upper
11.14
20, 2σ
Bollinger lower
8.56
20, 2σ
50 / 200 cross
Golden
11.52 vs 10.63
Trend bias
Above 200
+0.68%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.48
Less volatile than market
Correlation to SPY
0.05
Largely independent
Realised vol 30D
88.6%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-71.8%
Peak to trough
Max drawdown 5Y
-96.3%
Peak to trough
ATR 14
0.58
5.40% of price
Beta (reported)
1.79
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | Evercore ISI Group | UPGRADE | In-Line | Outperform |
| Jul 16, 26 | Wolfe Research | DOWNGRADE | Peer Perform | Underperform |
| Jul 10, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Jun 16, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jun 15, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jun 15, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Jun 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 13, 26 | Bernstein | MAINTAINED | Market Perform | Market Perform |
| May 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 12, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| May 12, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Apr 28, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
Headlines
Kenyan farmers turn to bugs as organic demand grows
AFP · 3m ago
FRN Variable Rate Fix
Business Wire · 3m ago
IHCL to merge Oriental Hotels under proposed share-swap deal
Hotel Management Network · 4m ago
Houlihan Lokey (HLI): Buy, Sell, or Hold Post Q2 Earnings?
StockStory · 6m ago
Hohhot, Inner Mongolia: Converting Prairie Winds into Computing Power
ACCESS Newswire · 6m ago
LIVE: US unveils new sanctions on Iran
Yahoo Finance Video · 7m ago
CPK chooses T-ROC Global to deploy automated food kiosks
Verdict Food Service · 8m ago
New IFT White Paper Provides Blueprint for Building a Future-Ready Food Science Workforce
Business Wire · 8m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.